{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:39:17Z","timestamp":1767141557995,"version":"build-2238731810"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T00:00:00Z","timestamp":1388707200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s11255-013-0637-2","type":"journal-article","created":{"date-parts":[[2014,1,2]],"date-time":"2014-01-02T04:58:09Z","timestamp":1388638689000},"page":"1145-1151","source":"Crossref","is-referenced-by-count":16,"title":["Calcitriol resistance in hemodialysis patients with secondary hyperparathyroidism"],"prefix":"10.1007","volume":"46","author":[{"given":"Armando L.","family":"Negri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent M.","family":"Brandemburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,3]]},"reference":[{"issue":"6","key":"637_CR1","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1172\/JCI111639","volume":"74","author":"E Slatopolsky","year":"1984","unstructured":"Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ (1984) Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 74(6):2136\u20132143","journal-title":"J Clin Invest"},{"issue":"4","key":"637_CR2","first-page":"186","volume":"55","author":"L Brandi","year":"2008","unstructured":"Brandi L (2008) 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol\u2014an active vitamin D analog: clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Dan Med Bull 55(4):186\u2013210","journal-title":"Dan Med Bull"},{"issue":"5","key":"637_CR3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1067\/mlc.2002.122819","volume":"139","author":"AJ Brown","year":"2002","unstructured":"Brown AJ, Finch J, Slatopolsky E (2002) Differential effects of 19-nor-1, 25-dihydroxyvitamin D(2) and 1, 25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. J Lab Clin Med 139(5):279\u2013284","journal-title":"J Lab Clin Med"},{"key":"637_CR4","doi-asserted-by":"crossref","unstructured":"National Kidney Foundation (2003) K\/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:S1\u2013S201","DOI":"10.1016\/S0272-6386(03)00905-3"},{"issue":"Suppl 5","key":"637_CR5","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1053\/ajkd.2001.28114","volume":"38","author":"F Llach","year":"2001","unstructured":"Llach F, Yudd M (2001) Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 38(Suppl 5):S45\u2013S50","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"637_CR6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/0886022X.2011.647298","volume":"34","author":"HZ Tonbul","year":"2012","unstructured":"Tonbul HZ, Solak Y, Atalay H, Turkmen K, Altintepe L (2012) Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study. Ren Fail 34(3):297\u2013303","journal-title":"Ren Fail"},{"issue":"1","key":"637_CR7","first-page":"59","volume":"22","author":"A Capuano","year":"2009","unstructured":"Capuano A, Serio V, Pota A, Memoli B, Andreucci VE (2009) Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients. J Nephrol 22(1):59\u201368","journal-title":"J Nephrol"},{"issue":"3","key":"637_CR8","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/j.1523-1755.2005.00178.x","volume":"67","author":"JJ Kazama","year":"2005","unstructured":"Kazama JJ, Sato F, Omori K, Hama H, Yamamoto S, Maruyama H, Narita I, Gejyo F, Yamashita T, Fukumoto S, Fukagawa M (2005) Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 67(3):1120\u20131125","journal-title":"Kidney Int"},{"issue":"1","key":"637_CR9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1542-4758.2010.00514.x","volume":"15","author":"C Vulpio","year":"2011","unstructured":"Vulpio C, Maresca G, Distasio E, Cacaci S, Panocchia N, Luciani G, Bossola M (2011) Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: responsiveness is related to parathyroid gland size. Hemodial Int 15(1):69\u201378","journal-title":"Hemodial Int"},{"key":"637_CR10","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1111\/j.1523-1755.2005.09428.x","volume":"94","author":"M Ketteler","year":"2005","unstructured":"Ketteler M, Gross ML, Ritz E (2005) Calcification and cardiovascular problems in renal failure. Kidney Int Suppl 94:S120\u2013S127","journal-title":"Kidney Int Suppl"},{"key":"637_CR11","first-page":"S1","volume":"113","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD\u2013MBD Work Group","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD\u2013MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD\u2013MBD). Kidney Int Suppl 113:S1\u2013S130","journal-title":"Kidney Int Suppl"},{"issue":"6","key":"637_CR12","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","volume":"26","author":"J Floege","year":"2011","unstructured":"Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, Kronenberg F, Marcelli D, Passlick-Deetjen J, Schernthaner G, Fouqueray B, Wheeler DC (2011) ARO Investigators Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 26(6):1948\u20131955","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"637_CR13","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/ndt\/gfn613","volume":"24","author":"A Covic","year":"2009","unstructured":"Covic A, Kothawala P, Bernal M, Robbins S, Chalian A, Goldsmith D (2009) Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 24(5):1506\u20131523","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"637_CR14","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5002769","volume":"73","author":"FC Barreto","year":"2008","unstructured":"Barreto FC, Barreto DV, Moys\u00e9s RM, Neves KR, Canziani ME, Draibe SA, Jorgetti V, Carvalho AB (2008) K\/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 73(6):771\u2013777","journal-title":"Kidney Int"},{"issue":"4","key":"637_CR15","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1681\/ASN.2004070573","volume":"16","author":"M Teng","year":"2005","unstructured":"Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hern\u00e1n MA, Camargo CA Jr, Thadhani R (2005) Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16(4):1115\u20131125","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"637_CR16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000346846","volume":"37","author":"F Duranton","year":"2013","unstructured":"Duranton F, Rodriguez-Ortiz ME, Duny Y, Rodriguez M, Daur\u00e8s JP, Argil\u00e9s A (2013) Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis. Am J Nephrol 37(3):239\u2013248","journal-title":"Am J Nephrol"},{"issue":"2","key":"637_CR17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1542-4758.2009.00424.x","volume":"14","author":"SG Achinger","year":"2010","unstructured":"Achinger SG, Mizani MR, Ayus JC (2010) Use of 3-hour daily hemodialysis and paricalcitol in patients with severe secondary hyperparathyroidism: a case series. Hemodial Int 14(2):193\u2013199","journal-title":"Hemodial Int"},{"issue":"2","key":"637_CR18","first-page":"70","volume":"5","author":"V Filiopoulos","year":"2007","unstructured":"Filiopoulos V, Malegos I, Stefanopoulou E, Patrikarea A (2007) Paricalcitol in dialysis patients with calcitriol\u2014resistant secondary hyperparathyroidism. BANTAO Journal 5(2):70\u201373","journal-title":"BANTAO Journal"},{"issue":"8","key":"637_CR19","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/ki.2011.226","volume":"80","author":"D Hansen","year":"2011","unstructured":"Hansen D, Rasmussen K, Danielsen H, Meyer-Hofmann H, Bacevicius E, Lauridsen TG, Madsen JK, Tougaard BG, Marckmann P, Thye-Roenn P, Nielsen JE, Kreiner S, Brandi L (2011) No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial. Kidney Int 80(8):841\u2013850","journal-title":"Kidney Int"},{"issue":"4","key":"637_CR20","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","volume":"26","author":"P Raggi","year":"2011","unstructured":"Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J, ADVANCE Study Group (2011) The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26(4):1327\u20131339","journal-title":"Nephrol Dial Transplant"},{"issue":"26","key":"637_CR21","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"GM Chertow","year":"2012","unstructured":"EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Dr\u00fceke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367(26):2482\u20132494","journal-title":"N Engl J Med"},{"key":"637_CR22","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/sj.ki.5002800","volume":"73","author":"TB Drueke","year":"2008","unstructured":"Drueke TB (2008) Is parathyroid hormone measurement useful for the diagnosis of renal bone disease? Kidney Int 73:674\u2013676","journal-title":"Kidney Int"},{"key":"637_CR23","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2215\/CJN.09471209","volume":"5","author":"C Gardham","year":"2010","unstructured":"Gardham C, Stevens PE, Delaney MP et al (2010) Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receivinbg hemodialysis. Clin J Am Soc Nephrol 5:1261\u20131267","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"637_CR24","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","volume":"63","author":"SM Sprague","year":"2003","unstructured":"Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D (2003) Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63(4):1483\u20131490","journal-title":"Kidney Int"},{"key":"637_CR25","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1681\/ASN.V73506","volume":"7","author":"P Ure\u00f1a","year":"1996","unstructured":"Ure\u00f1a P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC (1996) Plasma total versus bone alkaline phosphatase as marker of bone turnover in hemodialysis patients. J Am Soc Nephrol 7:506\u2013512","journal-title":"J Am Soc Nephrol"},{"key":"637_CR26","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1159\/000189578","volume":"75","author":"S Fletcher","year":"1997","unstructured":"Fletcher S, Jones RG, Rayner HC et al (1997) Assessment of renal osteodystrophy in dialysis patients: use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron 75:412\u2013419","journal-title":"Nephron"},{"key":"637_CR27","doi-asserted-by":"crossref","first-page":"296","DOI":"10.5414\/CNP70296","volume":"70","author":"G Lehman","year":"2008","unstructured":"Lehman G, Ott U, Kaemmerer D, Shuetze J, Wolf FG (2008) Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease stages 3\u20135. Clin Nephrol 70:296\u2013305","journal-title":"Clin Nephrol"},{"key":"637_CR28","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/oxfordjournals.ndt.a027457","volume":"11","author":"MM Coutteneye","year":"1996","unstructured":"Coutteneye MM, D\u00b4Haese PC, Van Hoof VO et al (1996) Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 11:1065\u20131072","journal-title":"Nephrol Dial Transplant"},{"key":"637_CR29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cca.2006.02.029","volume":"371","author":"E Cavalier","year":"2006","unstructured":"Cavalier E, Delanaye P, Collette J et al (2006) Evaluation of different bone markers in haemodialysis patients. Clin Chim Acta 371:107\u2013111","journal-title":"Clin Chim Acta"},{"key":"637_CR30","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/ndt\/gfg144","volume":"18","author":"H Reichel","year":"2003","unstructured":"Reichel H, Esser A, Roth HJ, Schmidt-Gayk H (2003) Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 18:759\u2013768","journal-title":"Nephrol Dial Transplant"},{"key":"637_CR31","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/ki.2012.77","volume":"82","author":"S Sardiwal","year":"2012","unstructured":"Sardiwal S, Gardham C, Coleman AE et al (2012) Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients. Kidney Int 82:100\u2013105","journal-title":"Kidney Int"},{"issue":"3","key":"637_CR32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1359\/jbmr.1998.13.3.325","volume":"13","author":"MR Haussler","year":"1998","unstructured":"Haussler MR, Whitfield GK, Haussler CA et al (1998) The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13(3):325\u2013349","journal-title":"J Bone Miner Res"},{"issue":"15","key":"637_CR33","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/hmg\/ddh169","volume":"13","author":"S Nejentsev","year":"2004","unstructured":"Nejentsev S, Godfrey L, Snook H et al (2004) Comparative high resolution analysis of linkage disequilibrium and tag single nucleotide polymorphisms between populations in the vitamin D receptor gene. Hum Mol Genet 13(15):1633\u20131639","journal-title":"Hum Mol Genet"},{"issue":"2","key":"637_CR34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.gene.2004.05.014","volume":"338","author":"AG Uitterlinden","year":"2004","unstructured":"Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP (2004) Genetics and biology of vitamin D receptor polymorphisms. Gene 338(2):143\u2013156","journal-title":"Gene"},{"issue":"6","key":"637_CR35","first-page":"843","volume":"21","author":"D Alvarez-Hernandez","year":"2008","unstructured":"Alvarez-Hernandez D, Naves-Diaz M, Gomez-Alonso C, Coto E, Cannata-Andia JB (2008) Tissue-specific effect of VDR gene polymorphisms on the response to calcitriol. J Nephrol 21(6):843\u2013849","journal-title":"J Nephrol"},{"issue":"1\u20132","key":"637_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2006.02.016","volume":"371","author":"JM Valdivielso","year":"2006","unstructured":"Valdivielso JM, Fernandez E (2006) Vitamin D receptor polymorphisms and diseases. Clin Chim Acta 371(1\u20132):1\u201312","journal-title":"Clin Chim Acta"},{"issue":"8","key":"637_CR37","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/oxfordjournals.ndt.a027783","volume":"12","author":"S Schmidt","year":"1997","unstructured":"Schmidt S, Chudek J, Karkoszka H et al (1997) The BsmI vitamin D-receptor polymorphism and secondary hyperparathyroidism. Nephrol Dial Transplant 12(8):1771\u20131772","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"637_CR38","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1046\/j.1523-1755.1998.00142.x","volume":"54","author":"P Messa","year":"1998","unstructured":"Messa P, Sindici C, Cannella G et al (1998) Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 54(5):1704\u20131713","journal-title":"Kidney Int"},{"issue":"10","key":"637_CR39","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1681\/ASN.V8101546","volume":"8","author":"E Fern\u00e1ndez","year":"1997","unstructured":"Fern\u00e1ndez E, Fibla J, Betriu A, Piulats JM, Almirall J, Montoliu J (1997) Association between vitamin D receptor gene polymorphism and relative hypoparathyroidism in patients with chronic renal failure. J Am Soc Nephrol 8(10):1546\u20131552","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"637_CR40","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/ajkd.1998.v32.pm9740163","volume":"32","author":"Y Nagaba","year":"1998","unstructured":"Nagaba Y, Heishi M, Tazawa H, Tsukamoto Y, Kobayashi Y (1998) Vitamin D receptor gene polymorphisms affect secondary hyperparathyroidism in hemodialyzed patients. Am J Kidney Dis 32(3):464\u2013469","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"637_CR41","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/ajcp\/112.3.366","volume":"112","author":"J Tagliabue","year":"1999","unstructured":"Tagliabue J, Farina M, Imbasciati E, Vergani C, Annoni G (1999) BsmI polymorphism of the vitamin D receptor gene in hyperparathyroid or hypoparathyroid dialysis patients. Am J Clin Pathol 112(3):366\u2013370","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"637_CR42","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1046\/j.1523-1755.1999.00678.x","volume":"56","author":"MP Marco","year":"1999","unstructured":"Marco MP, Mart\u00ednez I, Amoedo ML et al (1999) Vitamin D receptor genotype influences parathyroid hormone and calcitriol levels in predialysis patients. Kidney Int 56(4):1349\u20131353","journal-title":"Kidney Int"},{"issue":"2","key":"637_CR43","first-page":"111","volume":"56","author":"MP Marco","year":"2001","unstructured":"Marco MP, Mart\u00ednez I, Betriu A, Craver L, Fibla MJ, Fern\u00e1ndez E (2001) Influence of Bsml vitamin D receptor gene polymorphism on the response to a single bolus of calcitriol in hemodialysis patients. Clin Nephrol 56(2):111\u2013116","journal-title":"Clin Nephrol"},{"issue":"1","key":"637_CR44","first-page":"116","volume":"16","author":"M Borr\u00e0s","year":"2003","unstructured":"Borr\u00e0s M, Torregrossa V, Oliveras A et al (2003) BB genotype of the vitamin D receptor gene polymorphism postpones parathyroidectomy in hemodialysis patients. J Nephrol 16(1):116\u2013120","journal-title":"J Nephrol"},{"key":"637_CR45","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1046\/j.1523-1755.63.s85.6.x","volume":"85","author":"D Alvarez-Hern\u00e1ndez","year":"2003","unstructured":"Alvarez-Hern\u00e1ndez D, Naves M, Santamar\u00eda I, Men\u00e1rguez J, Torregrosa V, Cannata J (2003) Response of parathyroid glands to calcitriol in culture: Is this response mediated by the genetic polymorphisms in vitamin D receptor? Kidney Int Suppl 85:S19\u2013S22","journal-title":"Kidney Int Suppl"}],"updated-by":[{"DOI":"10.1007\/s11255-014-0898-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2014,12,14]],"date-time":"2014-12-14T00:00:00Z","timestamp":1418515200000}}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-013-0637-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-013-0637-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-013-0637-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T23:53:16Z","timestamp":1647820396000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-013-0637-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,3]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["637"],"URL":"https:\/\/doi.org\/10.1007\/s11255-013-0637-2","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,3]]}}}